Current approaches for optimizing the benefit of biologic therapy in ulcerative colitis
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Current approaches for optimizing the benefit of biologic therapy in ulcerative colitis
Authors
Keywords
-
Journal
Therapeutic Advances in Gastroenterology
Volume 9, Issue 4, Pages 548-559
Publisher
SAGE Publications
Online
2016-04-20
DOI
10.1177/1756283x16643242
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-Tumor Necrosis Factor Agents
- (2016) Jordan Axelrad et al. Clinical Gastroenterology and Hepatology
- Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis
- (2016) Johannan F. Brandse et al. Clinical Gastroenterology and Hepatology
- Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
- (2015) L Peyrin-Biroulet et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Concentrations of 6-Thioguanine Nucleotide Correlate With Trough Levels of Infliximab in Patients With Inflammatory Bowel Disease on Combination Therapy
- (2015) Andres J. Yarur et al. Clinical Gastroenterology and Hepatology
- An Accelerated Infliximab Induction Regimen Reduces the Need for Early Colectomy in Patients With Acute Severe Ulcerative Colitis
- (2015) David J. Gibson et al. Clinical Gastroenterology and Hepatology
- 592 Histological Normalization Is Associated With Superior Relapse Free Survival Compared to Histological Activity and Histological Quiescence in Ulcerative Colitis
- (2015) Britt Christensen et al. GASTROENTEROLOGY
- Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
- (2015) Niels Vande Casteele et al. GASTROENTEROLOGY
- Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis
- (2015) Johannan F. Brandse et al. GASTROENTEROLOGY
- Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel Disease
- (2015) Joana Torres et al. GASTROENTEROLOGY
- Clinical Practice Guidelines for the Medical Management of Nonhospitalized Ulcerative Colitis: The Toronto Consensus
- (2015) Brian Bressler et al. GASTROENTEROLOGY
- The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study
- (2015) Andres J Yarur et al. GUT
- Disease Outcome of Ulcerative Colitis in an Era of Changing Treatment Strategies: Results from the Dutch Population-Based IBDSL Cohort
- (2015) Steven F. G. Jeuring et al. Journal of Crohns & Colitis
- Optimal Doses of Methotrexate Combined with Anti-TNF Therapy to Maintain Clinical Remission in Inflammatory Bowel Disease
- (2015) R. J. Colman et al. Journal of Crohns & Colitis
- Immunopathogenesis of IBD: current state of the art
- (2015) Heitor S. P. de Souza et al. Nature Reviews Gastroenterology & Hepatology
- Early Trough Levels and Antibodies to Infliximab Predict Safety and Success of Reinitiation of Infliximab Therapy
- (2014) Filip Baert et al. Clinical Gastroenterology and Hepatology
- Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis
- (2014) Omoniyi J. Adedokun et al. GASTROENTEROLOGY
- Proactive Therapeutic Concentration Monitoring of Infliximab May Improve Outcomes for Patients with Inflammatory Bowel Disease
- (2014) Byron P. Vaughn et al. INFLAMMATORY BOWEL DISEASES
- Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient
- (2013) Niels Vande Casteele et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Inflammation Is an Independent Risk Factor for Colonic Neoplasia in Patients With Ulcerative Colitis: A Case–Control Study
- (2013) David T. Rubin et al. Clinical Gastroenterology and Hepatology
- Association Between Pharmacokinetics of Adalimumab and Mucosal Healing in Patients With Inflammatory Bowel Diseases
- (2013) Xavier Roblin et al. Clinical Gastroenterology and Hepatology
- Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis
- (2013) William J. Sandborn et al. GASTROENTEROLOGY
- Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis
- (2013) Remo Panaccione et al. GASTROENTEROLOGY
- Therapeutic Drug Monitoring of Infliximab and Mucosal Healing in Inflammatory Bowel Disease
- (2013) Stephane Paul et al. INFLAMMATORY BOWEL DISEASES
- Feasibility of Endoscopic Assessment and Treating to Target to Achieve Mucosal Healing in Ulcerative Colitis
- (2013) Guillaume Bouguen et al. INFLAMMATORY BOWEL DISEASES
- Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
- (2013) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Predictors of relapse in patients with ulcerative colitis in remission after one-year of infliximab therapy
- (2013) Klaudia Farkas et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Clinical Study of the Relation between Mucosal Healing and Long-Term Outcomes in Ulcerative Colitis
- (2013) Kaoru Yokoyama et al. Gastroenterology Research and Practice
- The Epidemiology of Colectomy in Ulcerative Colitis: Results From a Population-Based Cohort
- (2012) Laura E Targownik et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Addition of an Immunomodulator to Infliximab Therapy Eliminates Antidrug Antibodies in Serum and Restores Clinical Response of Patients With Inflammatory Bowel Disease
- (2012) Shomron Ben–Horin et al. Clinical Gastroenterology and Hepatology
- Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum
- (2012) Shui-Long Wang et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study
- (2012) Casper Steenholdt et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
- (2011) William J. Sandborn et al. GASTROENTEROLOGY
- Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial
- (2011) W. Reinisch et al. GUT
- Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: A prospective, multicenter study
- (2011) Gianmichele Meucci et al. INFLAMMATORY BOWEL DISEASES
- Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease
- (2010) Waqqas Afif et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee
- (2010) Asher Kornbluth et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Advanced Age Is an Independent Risk Factor for Severe Infections and Mortality in Patients Given Anti–Tumor Necrosis Factor Therapy for Inflammatory Bowel Disease
- (2010) Mario Cottone et al. Clinical Gastroenterology and Hepatology
- Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis
- (2009) C H Seow et al. GUT
- Clinical implications of mucosal healing for the management of IBD
- (2009) Guillaume Pineton de Chambrun et al. Nature Reviews Gastroenterology & Hepatology
- Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study)
- (2008) Inger Camilla Solberg et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More